// App-Quantinova.ai

: Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

Researchers

Presenter

  • Gregory Russell Pond

Principal Investigators

  • Guru Sonpavde

  • Karim Fizazi

  • Johann S. De Bono

  • Ethan M Basch

  • Howard I. Scher

  • Matthew Raymond Smith

Medical Centers

  • McMaster University, Hamilton, ON, Canada

  • Dana-Farber Cancer Institute, Boston, MA

  • Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France

  • Institute of Cancer Research and The Royal Marsden NHS Trust Foundation, London, United Kingdom

  • University of North Carolina, Chapel Hill, NC

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • Canada

  • United States

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Cabozantinib

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved